Diagnostic test for the investigation of adrenocortical insufficiency.
Synacthen Depot should normally only be used for short-term therapy in conditions for which glucocorticoids are indicated in principle
In ulcerative colitis and Crohn’s disease, juvenile rheumatoid arthritis, or as adjunct therapy in patients with rheumatoid arthritis and osteoarthrosis.
Synacthen Depot may be particularly useful in patients unable to tolerate oral glucocorticoid therapy or in patients where normal therapeutic doses of glucocorticoids have been ineffective.
Therapeutic use: Initially, daily doses of Synacthen Depot should be given but after approximately 3 days, intermittent doses may be given.
Adults: Initially 1mg intramuscularly daily or 1mg every 12 hours in acute cases. After the acute symptoms of the disease have disappeared, treatment may be continued at a dose of 1mg every 2 to 3 days; in patients who respond well, the dosage may be reduced to 0.5mg every 2 to 3 days or 1mg per week.
Premature babies or neonates (less than 1 month): Due to the presence of benzyl alcohol, Synacthen Depot is contraindicated in premature babies and in neonates (less than one month). (See section 4.3 Contraindications).
Children aged 3 to 5 years: Initially 0.25 to 0.5mg intramuscularly daily; the maintenance dose is 0.25 to 0.5mg every 2 to 8 days.
Children aged 5 to 12 years: Initially 0.25 to 1mg intramuscularly daily; the maintenance dose is 0.25 to 1mg every 2 to 8 days.
Since Synacthen Depot stimulates the adrenal cortex to increase the output of glucocorticoids and mineralocorticoids, side effects associated with excessive adrenocorticotropic activity may be encountered, as well as those related to tetracosactide.